Evidence map›Paper›PMID 34009430›Full record

ArticleEuropean journal of nutrition2021

Dietary flavonoids are associated with longitudinal treatment outcomes in neovascular age-related macular degeneration.

Harshil Dharamdasani Detaram, Gerald Liew, Joshua R Lewis, Nicola P Bondonno, Catherine P Bondonno, Kim Van Vu, George Burlutsky, Jonathan M Hodgson, Paul Mitchell, Bamini Gopinath

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Harshil Dharamdasani DetaramCentre for Vision Research, Department of Ophthalmology and The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Gerald LiewCentre for Vision Research, Department of Ophthalmology and The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Joshua R LewisCentre for Kidney Research and The Westmead Institute for Medical Research, School of Public Health, University of Sydney, Sydney, NSW, Australia.
Nicola P BondonnoSchool of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
Catherine P BondonnoSchool of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
Kim Van VuCentre for Vision Research, Department of Ophthalmology and The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
George BurlutskyCentre for Vision Research, Department of Ophthalmology and The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Jonathan M HodgsonSchool of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
Paul MitchellCentre for Vision Research, Department of Ophthalmology and The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Bamini GopinathCentre for Vision Research, Department of Ophthalmology and The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia. bamini.gopinath@sydney.edu.au.ORCID http://orcid.org/0000-0003-3573-359X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess whether dietary intake of flavonoids are associated with longitudinal treatment outcomes of patients with neovascular age-related macular degeneration (nAMD).

methods547 participants with nAMD were recruited at baseline, 494 were followed-up after receiving 12 months of anti-vascular endothelial growth factor (anti-VEGF) therapy. Baseline dietary intake of flavonoids was determined using a validated food frequency questionnaire. At follow-up, presence of intra-retinal and sub-retinal fluid (IRF and SRF), retinal pigment epithelium detachment and measurements of central macular thickness (CMT) were recorded from optical coherence tomography scans. Visual acuity (VA) was documented using LogMAR charts.

resultsParticipants in the first tertile of intake of the flavonol quercetin, and the flavan-3-ols epigallocatechin-3-gallate and epigallocatechin had significantly worse vision than participants in the third tertile-multivariable-adjusted least square (LS) mean VA: 14.68 vs. 19.53 (p = 0.04); 14.06 vs. 18.89 (p = 0.04); 13.86 vs. 18.86 (p = 0.03), respectively. Participants in the first compared to the third tertile of flavan-3-ol, epigallocatechin-3-gallate and epigallocatechin intake all had a twofold higher risk of IRF, multivariable-adjusted p trend of: 0.03, 0.01 and 0.02, respectively. The first vs. the third tertile of tea intake had significantly worse vision (LS mean VA: 13.49 vs. 19.04, p = 0.02), increased risk of IRF (OR 2.13, 95% CI 1.18-3.85) and greater mean CMT (279.59 μm vs. 256.52 μm, p = 0.04).

conclusionsHigher intakes of dietary flavonoids, specifically flavonols and flavan-3-ols, could be associated with better long-term treatment outcomes in nAMD patients receiving anti-VEGF therapy. Confirmation of these associations in interventional studies could result in promising new therapeutic approaches to the treatment of nAMD.

Indexed as

Macular DegenerationRanibizumabAngiogenesis InhibitorsFollow-Up StudiesHumansPolyphenolsRetrospective StudiesSubretinal FluidTreatment OutcomeVascular Endothelial Growth Factor AAngiogenesis InhibitorsPolyphenolsRanibizumabVascular Endothelial Growth Factor AAge-related macular degenerationCatechinFlavonoidsRetinaTeaVision

Identifiers

PMID34009430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.